Subsequent Events	3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On April 12, 2022, the Company’s Board of Directors approved a reduction of the Company’s workforce (the “Workforce Reduction”) by approximately 83% across all areas of the Company, to a total of six remaining full-time employees. The Workforce Reduction follows the Company’s decision to discontinue development of tovinontrine, as well to discontinue its development plans with respect to IMR-261. The Workforce Reduction is expected to be substantially completed by the end of the second quarter of 2022. The Workforce Reduction is designed to substantially reduce the Company’s operating expenses while the Company undertakes a comprehensive assessment of its strategic options to maximize stockholder value. In connection with the Workforce Reduction, the Company expects to record a one-time restructuring charge of approximately $2.0 million to $2.2 million primarily related to severance, healthcare coverage and other employee termination-related costs in the second quarter of 2022. The Company expects to incur additional costs in connection with the termination of the Ardent and Forte Phase 2b clinical trials of tovinontrine and its decision to discontinue development of tovinontrine, however the amount of such costs are not determinable as of the date of this Quarterly Report on Form 10-Q.

Subsequent Events

3 Months Ended

Mar. 31, 2022

14. Subsequent Events

On April 12, 2022, the Company’s Board of Directors approved a reduction of the Company’s workforce (the “Workforce Reduction”) by approximately 83% across all areas of the Company, to a total of six remaining full-time employees. The Workforce Reduction follows the Company’s decision to discontinue development of tovinontrine, as well to discontinue its development plans with respect to IMR-261. The Workforce Reduction is expected to be substantially completed by the end of the second quarter of 2022. The Workforce Reduction is designed to substantially reduce the Company’s operating expenses while the Company undertakes a comprehensive assessment of its strategic options to maximize stockholder value.

In connection with the Workforce Reduction, the Company expects to record a one-time restructuring charge of approximately $2.0 million to $2.2 million primarily related to severance, healthcare coverage and other employee termination-related costs in the second quarter of 2022. The Company expects to incur additional costs in connection with the termination of the Ardent and Forte Phase 2b clinical trials of tovinontrine and its decision to discontinue development of tovinontrine, however the amount of such costs are not determinable as of the date of this Quarterly Report on Form 10-Q.